Qyuns Therapeutics Co., Ltd. (2509.HK) Comparison with companies in other sectors?

Qyuns Therapeutics Co., Ltd. has a share price of 222.07M. You can analyze Qyuns Therapeutics Co., Ltd. (2509.HK) competitors across different market sectors through stock heatmaps.

What are 2509.HK's NET and operating margins?

Qyuns Therapeutics Co., Ltd. (2509.HK) operating margin is around -2.06, and net profit margin is approximately -2.11 as of the latest reports.

In what way does 2509.HK's earnings per share (EPS) trend reflect its financial momentum?

Qyuns Therapeutics Co., Ltd. (2509.HK) EPS is -1.67 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Qyuns Therapeutics Co., Ltd. is -12.78, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Qyuns Therapeutics Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Qyuns Therapeutics Co., Ltd. like P/E which is -12.97, P/B which is 19.02, and PEG which is -0.92. Compare them with sector averages to evaluate if the stock is priced fairly.

Qyuns Therapeutics Co., Ltd.

2509.HK•HKSE

Healthcare

Biotechnology

HK$21.35

HK$1.05(5.17%)

Qyuns Therapeutics Co., Ltd. (2509.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-1.67

P/E Ratio

-12.78

ROE

-1.12%

Net Margin

-2.11%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.74B

Shares OutstandingTotal number of shares issued

$222.07M

Book Value/ShareNet worth per share

$1.00

Revenue/ShareAnnual revenue per share

$0.71

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.67

Net MarginNet income as percentage of revenue

-211.33%

Operating MarginOperating income as percentage of revenue

-205.53%

ROEReturn on shareholders' equity

-112.50%

ROAReturn on total assets

-34.11%

ROCEReturn on capital employed

-58.94%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.84

Cash/ShareCash and equivalents per share

$1.63

FCF YieldFree cash flow as percentage of market cap

-4.27%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2509.HKFinancial Ratios Analysis details for 2509.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2509.HKSector Benchmarking details for 2509.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Qyuns Therapeutics Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Qyuns Therapeutics Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Qyuns Therapeutics Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Qyuns Therapeutics Co., Ltd.

For Qyuns Therapeutics Co., Ltd., essential financial indicators include EPS -1.67, PE -12.78, and ROE -1.12. These key ratios reveal insights into Qyuns Therapeutics Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Qyuns Therapeutics Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Qyuns Therapeutics Co., Ltd.

Metrics like Net Margin -211.33% and ROA -34.11% shed light on how well Qyuns Therapeutics Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Qyuns Therapeutics Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Qyuns Therapeutics Co., Ltd.

Using ratios such as P/B Ratio 19.02 and PEG Ratio -0.92, investors can assess whether Qyuns Therapeutics Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Qyuns Therapeutics Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Qyuns Therapeutics Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 2.30 and Cash Flow $-0.84, provide a snapshot of Qyuns Therapeutics Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Qyuns Therapeutics Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Qyuns Therapeutics Co., Ltd.

Investing in Qyuns Therapeutics Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Qyuns Therapeutics Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;